Designs for phase I trials

Designs for Clinical Trials: Perspectives on Current Issues

Volumn , Issue , 2012, Pages 1-27

  Cheung, Ying Kuen ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943521778     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0140-7_1     Document Type: Chapter

References (47)

1. Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 17:1103-1120
2. Bekele BN, Thall PF (2004) Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J Am Stat Assoc 99:26-35
3. Bekele BN, Yuan J, Shen Y, Thall PF (2008) Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics 9:442-457
4. Braun TM (2002) The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Contr Clin Trials 23:240-256
5. Carbone PP, Krant MJ, Miller SP, Hall TC, Shnider BI, Colsky J, Horton J, Hosley H, Miller JM, Frie E, Schneiderman M (1965) The feasibility of using randomization schemes early in the clinical trials of new chemotherapeutic agents: Hydroxyurea. Clin Pharmacol Therapeut 6:17-24
6. Cheung YK (2002) On the use of nonparametric curves in phase I trials with low toxicity tolerance. Biometrics 58:237-240
7. Cheung YK (2005) Coherence principles in dose-finding studies. Biometrika 92:863-873
8. Cheung YK (2006) Dose-finding with delayed binary outcomes in cancer trials. In: Chevret S (ed) Statistical method for dose-finding experiments. Wiley, NY, pp 225-242
9. Cheung YK (2007) Sequential implementation of stepwise procedures for identifying the maximum tolerated dose. J Am Stat Assoc 102:1448-1461
10. Cheung YK (2008) Dose-finding by the continual reassessment method, R package version 0.1-2. http://www.r-project.org
11. Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177-1182
12. Cheung YK, Chappell R (2002) A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 58:671-674
13. Cheung YK, Elkind MSV (2010) Stochastic approximation with virtual observations for dose finding on discrete levels. Biometrika 97:109-121
14. Cheung YK, Gordon PH, Levin B (2006) Selecting promising ALS therapies in clinical trials. Neurology 67:1748-1751
15. Dixon WJ, Mood AM (1948) A method for obtaining and analyzing sensitivity data. J Am Stat Assoc 60:967-978
16. Durham SD, Flournoy N (1994) Random walks for quantile estimation. In: Gupta S, Berger J (eds) Statistical decision theory and related topics V. Springer, New York, pp 467-476
17. Durham SD, Flournoy N, Rosenberger WF (1997) A random walk rule for phase I clinical trials. Biometrics 53:745-760
18. Elkind MSV, Sacco RL, MacArthur RB, Fink DJ, Peerschke E, Andrews H, Neils G, Stillman J, Corporan T, Leifer D, Cheung K (2008) The Neuroprotection with statin therapy for acute recovery trial (NeuSTART): An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischeme stroke. Int J Stroke 3:210-218
19. Faires D (1994) Practical modifications of the continal reassessment method for phase I cancer trials. J Biopharm Stat 4:147-164
20. Gasparini M, Eisele J (2000) A curve-free method for phase I clinical trials. Biometrics 56:609- 615
21. Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161
22. Ji Y, Li Y, Bekele BN (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4:235-244
23. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM (1994) A comparison of two phase I trial designs. Stat Med 13:1799-1806
24. Lee SM, Hershman D, Martin P, Leonard J, Cheung K (2009) Validation of toxicity burden score for use in phase I clinical trials. J Clin Oncol 27 (Suppl.), 15s (abstr. 2514)
25. Lee SM, Cheng B, Cheung YK (2001) Continual reassessment method with multiple toxicity constraints. Biostatistics. 12:386-398
26. Leonard JP, Furman RR, Cheung YKK, Feldman EJ, Cho HJ, Vose JM, Nichols G, Glynn PW, Joyce MA, Ketas J, Ruan J, Carew J, Niesvizky R, LaCasce A, Chadburn A, Cesarman E, Coleman M (2005) Phase I/II trial of bortezomib plus CHOP-Rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results. Blood 106:147A-147A
27. McLeish DL, Tosh D (1990) Sequential designs in bioassay. Biometrics 46:103-116
28. Muller J, McGinn C, Normolle D et al (2004) A phase I trial using the time-to-event continual reassessment strategy to escalate cisplatin with gemcitabine and radiation therapy for pancreatic cancer. J Clin Oncol 22:238-243
29. Naylor J, Smith A (1982) Applications of a method for the efficient computation of posterior distributions. Appl Stat 31:214-225
30. Normolle D, Lawrence T (2006) Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 24:4426-4433
31. O'Quigley J, Shen LZ (1996) Continual reassessment method: A likelihood approach. Biometrics 52:673-684
32. O'Quigley J, PepeM, Fisher L (1990) Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48
33. O'Quigley JO, Hughes MD, Fenton T (2001) Dose-finding designs for HIV studies. Biometrics 57:1018-1029
34. R Development Core Team (2008) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, http://www.r-project.org
35. Ratain MJ, Mick R, Schilsky RL, Siegler M (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637- 1643
36. Rosa DD, Harris J, Jayson GC (2006) The best guess approach to phase I trial design. J Clin Oncol 24:206-208
37. Schneiderman MA (1965) How can we find an optimal dose? Toxicol Appl Pharmacol 7:44-53
38. Shen LZ, O'Quigley J (1996) Consistency of continual reassessment method under model misspecification. Biometrika 83:395-405
39. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147
40. Storer B (1989) Design and analysis of phase I clinical trials. Biometrics 45:925-937
41. Storer B, DeMets D (1987) Current phase I/II designs: Are they adequate? J Clin Res Drug Dev 1:121-130
42. Thall PF, Cook JD (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60:684- 693
43. Wald A (1945) Sequential tests of statistical hypotheses. Ann Math Stat 16:117-186
44. Wald A, Wolfowitz J (1948) Optimum character of the sequential probability ratio test. Ann Math Stat 19:326-339
45. Yin G, Li Y, Ji Y (2006) Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratio. Biometrics 62:777-787
46. Yuan Z, Chappell R, Bailey H (2007) The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics 63:173-179
47. Zacks S, Rogatko A, Babb J (1998) Optimal Bayesian-feasible dose escalation for cancer phase I trials. Stat Probab Lett 38:215-220